Related Experiment Video

Updated: Sep 1, 2026

Assessment of Child Anthropometry in a Large Epidemiologic Study
09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

[QT interval dispersion and the type of obesity in women]

K Mizia-Stec1, T Mandecki, B Zahorska-Markiewicz

  • 1II Klinika Kardiologii Sl. AM w Katowicach.

Polskie Archiwum Medycyny Wewnetrznej
|March 31, 2000
PubMed

Insights

Obesity increases QT interval dispersion, a marker of heart repolarization inhomogeneity, raising arrhythmia risk. Upper body obesity showed higher QTd compared to lower body obesity in women.

Area of Science:

  • Cardiology
  • Obesity Research
  • Electrophysiology

Background:

  • Obesity is linked to increased risk of sudden cardiac death.
  • Ventricular arrhythmias are common causes of cardiac events.
  • Delayed cardiac repolarization, indicated by prolonged QT interval, precedes arrhythmias.

Purpose of the Study:

  • To assess QT interval dispersion (QTd) in obese women.
  • To determine the relationship between obesity and QTd.
  • To investigate the influence of obesity type on QTd.

Main Methods:

  • 62 obese women and 15 healthy women were studied.
  • Obese women were categorized by waist-to-hip ratio (WHR) into upper body, WHR 0.75-0.85, and lower body obesity subgroups.
  • Standard 12-lead ECG, echocardiography were used to calculate QTd, QTdc, QTdR, left ventricular mass (LVM), and LVMI.

Main Results:

  • Obese women exhibited significantly higher QTd, QTdc, QTdR, LVM, and LVMI compared to controls.
  • A positive correlation was found between BMI and LVM/LVMI.
  • Subgroup 1a (upper body obesity) showed significantly higher QTdR than subgroup 1c (lower body obesity).

Conclusions:

  • QT interval dispersion is increased in obese women.
  • Increased QTd in obesity is associated with obesity type, particularly upper body obesity.
Abstract

More Related Videos

Assessment of Physical Activity Intensity with Accelerometers and Oxygen Consumption08:45

Assessment of Physical Activity Intensity with Accelerometers and Oxygen Consumption

Published on: June 20, 2025

Multidisciplinary Approach to Obesity Management: A Case Report05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Related Concept Videos

Quartile01:15

Quartile

Quartiles are numbers that separate the data into quarters. Quartiles may or may not be part of the data. To find the quartiles, first, find the median or second quartile. The first quartile, Q1, is the middle value of the lower half of the data, and the third quartile, Q3, is the middle value, or median, of the upper half of the data. To get the idea, consider the same data set:
1; 1; 2; 2; 4; 6; 6.8; 7.2; 8; 8.3; 9; 10; 10; 11.5
The median or second quartile is seven. The lower half of the...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...